Skip to main content

4 articles related to "Companion Diagnostics Cdx"

No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.

Articles

Review

Published on 19 Jun 2015

Personalized medicine for pathological circadian dysfunctions

in Drugs Outcomes Research and Policies

Rachel L. Skelton
Jon M. Kornhauser
Barbara A. Tate

Frontiers in Pharmacology

doi 10.3389/fphar.2015.00125

7,249 views
8 citations

Review

Published on 16 May 2014

Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects

in Pharmacology of Anti-Cancer Drugs

Dana Olsen
Jan Trøst Jørgensen

Frontiers in Oncology

doi 10.3389/fonc.2014.00105

46,140 views
88 citations

Original Research

Published on 28 Jan 2016

A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics

in Genetics of Aging

Dee Luo
James A. Smith
Nick A. Meadows
A. Schuh
Katie E. Manescu
Kim Bure
Benjamin Davies
Rob Horne
Mike Kope
David L. DiGiusto

Frontiers in Genetics

doi 10.3389/fgene.2015.00357

12,452 views
14 citations

Review

Published on 01 Apr 2014

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

in Pharmacology of Anti-Cancer Drugs

Sai-Hong Ignatius Ou

Frontiers in Oncology

doi 10.3389/fonc.2014.00058

14,816 views
24 citations